<p>Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson’s disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Clinical utility of digital technologies in Parkinson’s disease

  • Björn Falkenburger,
  • Alessandra Fanciulli,
  • Monika Pötter-Nerger,
  • Thilo van Eimeren,
  • Joseph Classen,
  • Günter Höglinger,
  • Christoph Redecker,
  • Jürgen Winkler,
  • Jochen Klucken

摘要

Digital health technologies (DHTs) are on the verge of changing treatment of Parkinson’s disease (PD). This narrative overview article describes DHTs that are already used or in development, focusing on technologies available in Germany and on their clinical utility. Examples include applications that are primarily used by patients, i.e., tools for patient education and empowerment, but also stand-alone interventions improving clinical outcomes including motor and non-motor symptoms. In Germany, these patient-centered DHTs fall under the HTA framework of digital health applications (DIGA). DHT for telemonitoring, in contrast, are designed to support physicians and other healthcare providers and therefore medical devices. DHT are also used increasingly as exploratory endpoints in trials testing neuroprotective treatments.